Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Search Study Connect
  • NCT03899155

Recruiting

Pan Tumor Rollover Study - CA209-8TT

Updated: 15 April, 2025   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.
Print this page CA209-8TT
Download Study Participant’s Guide

SELECT LANGUAGE

Trial Details

  • Phase 2

    Phase

  • Gender(s)

  • 18+

    Age Range

  • 171

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: A1: Nivolumab Monotherapy Dose 1
Drug: Nivolumab
Experimental: A2: Nivolumab Monotherapy Dose 2
Drug: Nivolumab
Experimental: B1: Nivolumab + Ipilimumab
Drug: Ipilimumab, Nivolumab
Experimental: B2: Nivolumab + Ipilimumab + Cabozantinib
Drug: Ipilimumab, Cabozantinib, Nivolumab
Experimental: B3: Nivolumab + Ipilimumab + Trametinib
Drug: Ipilimumab, Trametinib, Nivolumab
Experimental: C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1
Drug: Nivolumab + Relatlimab
Experimental: C10: Relatlimab + Nivolumab SAV Dose 4
Drug: Relatlimab, Nivolumab
Experimental: C11: Relatlimab + Nivolumab SAV + PDCT Dose 2
Drug: Relatlimab, Nivolumab
Experimental: C12: Relatlimab + Nivolumab SAV Dose 5
Drug: Relatlimab, Nivolumab
Experimental: C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1
Drug: Relatlimab, Nivolumab
Experimental: C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2
Drug: Nivolumab + Relatlimab
Experimental: C4: Relatlimab + Nivolumab SAV Dose 2
Drug: Relatlimab, Nivolumab
Experimental: C5: Relatlimab + Nivolumab + Ipilimumab
Drug: Ipilimumab, Nivolumab
Experimental: C6: Relatlimab + Nivolumab + Capecitabine
Drug: Nivolumab + Relatlimab, Capecitabine
Experimental: C7: Relatlimab + Nivolumab SAV Dose 3
Drug: Relatlimab, Nivolumab
Experimental: C8: Relatlimab + Nivolumab SAV + PDCT Dose 1
Drug: Relatlimab, Nivolumab
Experimental: C9: Relatlimab + Nivolumab SAV + Bevacizumab
Drug: Relatlimab, Bevacizumab, Nivolumab
Experimental: D1: Nivolumab + Temozolomide
Drug: Temozolomide, Nivolumab
Experimental: D2: Nivolumab + Rucaparib
Drug: Rucaparib, Nivolumab
Experimental: D3: Nivolumab + Daratumumab
Drug: Daratumumab, Nivolumab
Experimental: D4: Nivolumab + Bevacizumab
Drug: Nivolumab
Experimental: E1: Bevacizumab Monotherapy
Drug: Bevacizumab
Experimental: E10: Pemetrexed Monotherapy
Drug: Pemetrexed
Experimental: E11: Pembrolizumab Monotherapy
Drug: Pembrolizumab
Experimental: E2: Regorafinib Monotherapy
Drug: Regorafinib
Experimental: E3: Leucovorin + Fluorouracil
Drug: Leucovorin
Experimental: E4: Leucovorin + Oxaliplatin + Fluorouracil
Drug: Leucovorin, Fluorouracil, Oxaliplatin
Experimental: E5: Enzalutamide Monotherapy
Drug: Enzalutamide
Experimental: E6: Sunitinib Monotherapy
Drug: Sunitinib
Experimental: E7: Rucaparib Monotherapy
Drug: Rucaparib
Experimental: E8: Capecitabine Monotherapy
Drug: Capecitabine
Experimental: E9: Cabozantinib Monotherapy
Drug: Cabozantinib

Key Eligibility Criteria

Inclusion Criteria: - Signed Written Informed Consent. - Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study. - On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study. - WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF. Exclusion Criteria: - Participant is not eligible for study treatment per the Parent Study eligibility criteria. - Participants not receiving clinical benefit as assessed by the Investigator. - Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant. - Other protocol-defined Inclusion/Exclusion Criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

466-SE-2100058